Artiva Biotherapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-25.0M | $-23.5M | $-20.8M | $-21.5M | $-21.3M | $-20.3M | $-16.1M | $-17.5M |
| Depreciation & Amortization | $692.0K | $666.0K | $666.0K | $662.0K | $641.0K | $628.0K | $614.0K | $627.0K |
| Depreciation | $700.0K | $600.0K | $700.0K | $600.0K | $600.0K | $600.0K | $600.0K | $600.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $1.9M | $1.6M | $1.6M | $1.6M | $1.5M | $2.1M | $2.2M | $1.9M |
| Net Cash from Operating Activities | $-20.4M | $-21.0M | $-14.7M | $-19.2M | $-23.0M | $-19.8M | $-14.7M | $-11.6M |
| Investing Activities | ||||||||
| Capital Expenditures | $415.0K | $242.0K | $421.0K | $600.0K | $1.1M | $511.0K | $64.0K | $96.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $17.6M | $15.3M | $16.0M | $16.3M | $21.1M | $10.0M | $-966.0K | $-130.6M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $283.3M | $-112.0K | $-121.0K | $-37.0K | $-72.0K | $239.0K | — | — |
| Net Change in Cash | $280.5M | $-5.7M | $1.2M | $-3.0M | $-1.9M | $-9.6M | $-15.6M | $21.6M |
| Free Cash Flow | $-20.8M | $-21.2M | $-15.1M | $-19.8M | $-24.0M | $-20.4M | $-14.7M | $-11.7M |